Patents by Inventor Giuseppe Ciaramella

Giuseppe Ciaramella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240156952
    Abstract: Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.
    Type: Application
    Filed: July 18, 2023
    Publication date: May 16, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
  • Patent number: 11918644
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: March 5, 2024
    Assignee: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Patent number: 11911453
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • Patent number: 11872278
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 16, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Publication number: 20240000917
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
    Type: Application
    Filed: May 24, 2023
    Publication date: January 4, 2024
    Applicant: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Publication number: 20230390379
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 7, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
  • Publication number: 20230381301
    Abstract: Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPIV3) F protein.
    Type: Application
    Filed: March 24, 2023
    Publication date: November 30, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Publication number: 20230374079
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: August 4, 2023
    Publication date: November 23, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
  • Publication number: 20230346907
    Abstract: The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 2, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 11802146
    Abstract: This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: October 31, 2023
    Assignees: ModernaTX, Inc., Vanderbilt University
    Inventors: Sunny Himansu, James E. Crowe, Jr., Giuseppe Ciaramella
  • Publication number: 20230310576
    Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: November 14, 2022
    Publication date: October 5, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
  • Publication number: 20230303632
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: February 28, 2023
    Publication date: September 28, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
  • Patent number: 11752206
    Abstract: Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 12, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
  • Publication number: 20230270836
    Abstract: The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: October 7, 2022
    Publication date: August 31, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
  • Patent number: 11696946
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 11, 2023
    Assignee: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Patent number: 11643441
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: May 9, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
  • Publication number: 20230114180
    Abstract: The disclosure relates to respiratory syncytial vims (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: August 30, 2022
    Publication date: April 13, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
  • Publication number: 20230116376
    Abstract: The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: August 12, 2022
    Publication date: April 13, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
  • Publication number: 20230070861
    Abstract: The invention features compositions and methods for introducing mutations into the hepatitis B virus (HBV) genome.
    Type: Application
    Filed: May 8, 2020
    Publication date: March 9, 2023
    Applicant: Beam Therapeutics Inc.
    Inventors: Elena SMEKALOVA, Michael PACKER, Francine GREGOIRE, Luis BARRERA, Giuseppe CIARAMELLA
  • Patent number: 11576961
    Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: February 14, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle